FAQ: Lantern Pharma's AI Platform Helping Hoth Therapeutics in Drug Development
Summary
Hoth Therapeutics is using Lantern Pharma's PredictBBB.ai platform to accelerate drug development by determining whether drug candidates can cross the blood-brain barrier, which helps reduce risk and improve candidate selection.
What is the main topic of this announcement?
Hoth Therapeutics is using Lantern Pharma’s AI-powered PredictBBB.ai platform to streamline and improve their drug development process, specifically for determining whether drug candidates can cross the blood-brain barrier.
What is PredictBBB.ai and what does it do?
PredictBBB.ai is a next-generation AI tool developed by Lantern Pharma that helps determine whether a drug candidate is able to cross the blood-brain barrier, with 94% accuracy in predicting this capability.
Why is crossing the blood-brain barrier important in drug development?
The ability to cross the blood-brain barrier is a common bottleneck and major holdup for many drug development companies, making it a critical factor in developing effective treatments for brain-related conditions.
What are the key benefits of using PredictBBB.ai for Hoth Therapeutics?
The platform helps accelerate development timelines, reduce risk, and improve candidate selection by accurately predicting blood-brain barrier penetration capabilities.
Which companies are involved in this collaboration?
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company that developed the PredictBBB.ai platform, and Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company using the platform.
How accurate is the PredictBBB.ai platform?
The platform offers 94% accuracy in predicting whether different drug candidates can cross the blood-brain barrier.
What is the leadership’s perspective on this collaboration?
Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the collaboration and how it can help deliver life-changing therapies for patients.
Where can investors find more information about Lantern Pharma?
The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.
What is BioMedWire and its role in this announcement?
BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences sectors that published this announcement and provides distribution services to reach target markets and investors.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 240851